Diabetic Nephropathies
Recent clinical, regulatory, research and industry developments relating to this disease.
Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy.
Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists.
Glucagon-like peptide-1 receptor agonists and kidney outcomes.
Mechanisms of hepatic and renal injury in lipid metabolism disorders in metabolic syndrome.
New insights into the role of immunity and inflammation in diabetic kidney disease in the omics era.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q1 2027.
- Q1 2027A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema
- Q3 2027A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
- Q3 2027Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau
- Q3 2027Semaglutide for Dialysis-Treated Patients - a Glucose Time in Range Study- DIALYSIS-TIR Study
- Q4 2027Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Clinical MilestonesView all 13Hide
- 2026-06-26A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular EdemaResults expected Q1 2027
- 2026-04-20A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 DiabetesResults expected Q3 2027
- 2026-03-18A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)Results expected Q1 2028
- 2026-02-17Diabetes Diagnosis, Management, Prevention and Education in Guinea-BissauResults expected Q3 2027
- 2026-01-13Semaglutide for Dialysis-Treated Patients - a Glucose Time in Range Study- DIALYSIS-TIR StudyResults expected Q3 2027
- 2029-02-28Evaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With MetforminWithdrawn
- 2028-07-31Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal SubstudyWithdrawn
- 2028-03-01A Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2028-02-01Phase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With MetforminWithdrawn
- 2027-01-01Comparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular EdemaWithdrawn
- 2029-02-28ClinicalEvaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With MetforminWithdrawn
- 2028-07-31ClinicalIntervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal SubstudyWithdrawn
- 2028-03-01ClinicalA Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2028-02-01ClinicalPhase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With MetforminWithdrawn
- 2027-01-01ClinicalComparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular EdemaWithdrawn
- 2026-06-30ClinicalMetformin Versus Standard of Care Treatment in Pregnant Women With Prediabetes: A Randomized TrialWithdrawn
- 2026-06-26ClinicalA Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular EdemaResults expected Q1 2027
- 2026-04-20ClinicalA Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 DiabetesResults expected Q3 2027
- 2026-03-18ClinicalA 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)Results expected Q1 2028
- 2026-02-17ClinicalDiabetes Diagnosis, Management, Prevention and Education in Guinea-BissauResults expected Q3 2027
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Diabetic Nephropathies12
- Diabetes Mellitus, Type 211
- Glucagon-Like Peptide-1 Receptor Agonists10
- Hypoglycemic Agents6
- Cardiovascular Diseases4
- Sodium-Glucose Transporter 2 Inhibitors4
- Kidney3
- Renal Insufficiency, Chronic3
Leading journals6
- International journal of molecular sciences4
- Cardiovascular diabetology3
- Diabetes & metabolism journal2
- American journal of kidney diseases : the official journal of the National Kidney Foundation1
- BioMed research international1
- Circulation1
Leading researchers8
- Cooper ME3
- Chen JY2
- Coughlan MT2
- Wu VC2
- Advani A1
- Agarwal R1
- Al-Sharea A1
- Alfonso F1
Affiliations (unnormalised)6
- Chia Nan University of Pharmacy and Science2
- College of Medicine2
- Monash University2
- National Taiwan University Hospital2
- The George Institute for Global Health2
- Albert Einstein College of Medicine1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Diabetic nephropathies are kidney injuries associated with diabetes mellitus that involve the glomeruli, arterioles, tubules, and interstitium. They are characterized clinically by persistent proteinuria, often beginning as microalbuminuria and progressing to overt albuminuria, with declining glomerular filtration rate and possible end-stage renal disease.
They arise in the setting of diabetes mellitus, with chronic hyperglycemia implicated as a major driver. The supplied literature also notes co-morbidity such as hypertension and age-related nephron loss as contributors to diabetic kidney disease.
The disease reflects microvascular and structural kidney damage in diabetes, with injury affecting multiple renal compartments. The literature highlights roles for renin-angiotensin system activation, oxidative stress, inflammatory signaling, and altered glomerular filtration rate, along with metabolic memory from advanced glycation end product accumulation and epigenetic change.
Chronic hyperglycemia and high blood pressure are the main risk factors described in the supplied literature. Diabetes itself, especially when accompanied by hypertension or age-related nephron loss, increases risk of kidney disease progression.
Standard management centers on blood glucose control, blood pressure control, and blockade of the renin-angiotensin system. The literature also identifies cardiovascular risk reduction and, in more recent treatment discussions, sodium-glucose cotransporter 2 inhibitors as an additional drug class used for diabetic kidney disease.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.